Palisade Bio (PALI) Stock Analysis: AI Score & Alternative Data
PALI alt-data: headcount climbing, web traffic lagging
Is Palisade Bio a buy right now? The alternative data says hold. This PALI stock analysis is built on the 25+ alternative data signals AltIndex tracks on Palisade Bio every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 54/100: a Hold. The stock trades at $2.06 with a $359M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 8.7% to 25 employees. The drag: web traffic down 21.6% to 3K monthly visits. That tension is what keeps the score mid-range.
PALI’s broader alt-data profile also covers Facebook followers (7K), and sentiment (100/100). Every signal links to its own page with full history, the PALI technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on PALI is just below.
Palisade Bio AI Stock Analysis
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's lead product candidate, LB1148, is designed to reduce perioperative surgical complications by preserving gut function.
Analysis generated September 2, 2026.
Recent Palisade Bio Stock Alerts
|
Palisade Bio | September 9 Price is down by -6.4% in the last 24h. |
|
Palisade Bio | September 8 Price is up by 6.2% in the last 24h. |
|
Palisade Bio | August 19 Price is up by 6.9% in the last 24h. |
|
Palisade Bio | August 18 Price is down by -6.1% in the last 24h. |
Palisade Bio Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 3K | 21.6% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 25 | 8.7% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 17 | 29.2% | |
| Stocktwits Mentions | 2 | 33.3% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 19K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 2K | 0% | |
| Facebook Followers | 7K | 6.8% | |
| Facebook Engagement | 3 | 95.6% |
About Palisade Bio (PALI)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
| Price | $2.06 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $359M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | 3.2 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Palisade Bio News
View more →
Palisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10 - GlobeNewswire |
|
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative ColitisJune 29 - GlobeNewswire |
|
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of DirectorsJune 11 - GlobeNewswire |
|
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences SymposiumJune 9 - GlobeNewswire |
|
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4MMay 17 - Yahoo Entertainment |
|
See Palisade Bio’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for PALI, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEPalisade Bio Earnings & Financial Performance
View all earnings →Palisade Bio Insider Trading Activity
View all →| Baltera Robert Jr. filed to sell 461,904 shares at $0.0. Jul 9 '26 |
| Baltera Robert Jr. filed to sell 436,904 shares at $0.0. Jul 8 '26 |
| Jones Mitchell Lawrence filed to sell 94,009 shares at $0.0. Jul 7 '26 |
| Baltera Robert Jr. filed to sell 416,904 shares at $0.0. Jul 7 '26 |
| Finley John David filed to sell 217,555 shares at $0.0. Jul 7 '26 |
Palisade Bio Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Palisade Bio
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Eyepoint PharmaceuticalsEYPT |
$4.23 0.5% | $355M | 32 |
 |
Sionna TherapeuticsSION |
$7.99 4.9% | $354M | 50 |
 |
Century TherapeuticsIPSC |
$1.94 0.0% | $351M | 53 |
 |
DiaMedica TherapeuticsDMAC |
$6.47 0.0% | $349M | 42 |
 |
Lexeo TherapeuticsLXEO |
$4.25 2.5% | $349M | 43 |
Explore Palisade Bio Data
Frequently Asked Questions: Palisade Bio (PALI)
Palisade Bio has an AltIndex AI Score of 54/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
54/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Palisade Bio (PALI) stock is $2.06 with a market cap of $359M.
As of today, Palisade Bio’s PE (Price to Earnings) ratio is 3.2.
View the latest Palisade Bio insider transactions to see recent buying and selling activity by company executives and directors.
Check the Palisade Bio congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The PALI stock price chart above shows Palisade Bio’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Palisade Bio technical analysis for RSI, moving averages, and more.
See the stocks similar to Palisade Bio section on this page for companies in the same industry ranked by market cap and AI Score.
